{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:32:41Z","timestamp":1740173561946,"version":"3.37.3"},"reference-count":42,"publisher":"Endocrinology Research Centre","issue":"2","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Primary hyperaldosteronism (PHA) is the most common form of endocrine hypertension. Until recently, the reason for the development of this condition was believed to be the presence of genetic mutations, however, many studies declare that the disease can be polyetiologic, be the result of genetic mutations and autoimmune triggers or cell clusters of aldosterone-producing cells diffusely located in the adrenal gland at the zona glonerulosa, zona fasculata, zona reticularis, as well as directly under the adrenal capsule. Recently, the actions of autoantibodies to type 1 angiotensin II receptors have been described in patients with renal transplant rejection, with preeclampsia, and with primary hyperaldosteronism. The diagnostic role of antibodies in both forms of PHA (aldosterone-producing adenoma and bilateral hyperaldosteronism) requires clarification. Diagnosis and confirmation of the focus of aldosterone hypersecretion is a multi-stage procedure that requires a long time and economic costs. The relevance of timely diagnosis of primary hyperaldosteronism is to reduce medical and social losses. This work summarizes the knowledge about genetic mutations and presents all the original studies devoted to autoantibodies in PHA, as well as discusses the diagnostic capabilities and limitations of the available methods of primary and differential diagnosis of the disease and the prospects for therapy.<\/jats:p>","DOI":"10.14341\/probl12783","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T08:23:05Z","timestamp":1651306985000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenetics of primary hyperaldosteronism: fundamental studies and their clinical prospects"],"prefix":"10.14341","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5645-9836","authenticated-orcid":true,"given":"S. K.","family":"Eristavi","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-1544","authenticated-orcid":true,"given":"N. M.","family":"Platonova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-8702","authenticated-orcid":true,"given":"E. A.","family":"Troshina","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Dutta RK, S\u00f6derkvist P, Gimm O. Genetics of primary hyperaldosteronism. Endocr Relat Cancer. 2016;23(10):R437-454. doi: https:\/\/doi.org\/10.1530\/ERC-16-0055","DOI":"10.1530\/ERC-16-0055"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Rossitto G, Regolisti G, Rossi E, et al. Elevation of Angiotensin-II Type-1-Receptor Autoantibodies Titer in Primary Aldosteronism as a Result of Aldosterone-Producing Adenoma. Hypertension. 2013;61(2):526-533. doi: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.202945","DOI":"10.1161\/HYPERTENSIONAHA.112.202945"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Meyer LS, Gong S, Reincke M, Williams TA. Angiotensin II Type 1 Receptor Autoantibodies in Primary Aldosteronism. Horm Metab Res. 2020;52(6):379-385. doi: https:\/\/doi.org\/10.1055\/a-1120-8647","DOI":"10.1055\/a-1120-8647"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Sabbadin C, Ceccato F, Ragazzi E, et al. Evaluation of angiotensin II type-1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role. J Clin Hypertens. 2018;20:1313-1318. doi: https:\/\/doi.org\/10.1111\/jch.13351","DOI":"10.1111\/jch.13351"},{"key":"ref5","unstructured":"Williams textbook of endocrinology (12th ed.). Philadelphia: Elsevier\/Saunders. Melmed, Shlomo., Robert Hardin Williams. Williams Textbook of Endocrinology."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Lemari\u00e9 CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin-Angiotensin-Aldosterone Syst. 2010;11(1):19-31. doi: https:\/\/doi.org\/10.1177\/1470320309347785","DOI":"10.1177\/1470320309347785"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Nishimoto K, Nakagawa K, Li D, et al. Adrenocortical Zonation in Humans under Normal and Pathological Conditions. J Clin Endocrinol Metab. 2010;95(5):2296-2305. doi: https:\/\/doi.org\/10.1210\/jc.2009-2010","DOI":"10.1210\/jc.2009-2010"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Omata K, Tomlins SA, Rainey WE. Aldosterone-Producing Cell Clusters in Normal and Pathological States. Horm Metab Res. 2017;49(12):951-956. doi: https:\/\/doi.org\/10.1055\/s-0043-122394","DOI":"10.1055\/s-0043-122394"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Seidel E, Schewe J, Scholl UI. Genetic causes of primary aldosteronism. Exp Mol Med 2019;51:1-12. doi: https:\/\/doi.org\/10.1038\/s12276-019-0337-9","DOI":"10.1038\/s12276-019-0337-9"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Vorokhobina NV, Shustov SB, Balandina KA, Galakhova RK. Genetic aspects of primary hyperaldosteronism and pheochromocytoma. Arterial Hypertension. 2017;23(3):178-185. (In Russ.). doi: https:\/\/doi.org\/10.18705\/1607-419X-2017-23-3-178-185","DOI":"10.18705\/1607-419X-2017-23-3-178-185"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone producing adenomas and secondary hypertension \/\/ Nature Genetics. 2013;45:440-444. doi: https:\/\/doi.org\/10.1038\/ng.2550","DOI":"10.1038\/ng.2550"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Zheng FF, Zhu LM, Nie AF, et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma. J Hypertension. 2015;65(3):622-628. doi: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03346","DOI":"10.1161\/HYPERTENSIONAHA.114.03346"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Stindl J, Tauber P, Sterner C, et al. Pathogenesis of adrenal aldosterone producing adenomas carrying mutations of the Na(+)\/K(+)-ATPase. J Endocrinology. 2015;156(12):4582-4591. doi: https:\/\/doi.org\/10.1210\/en.2015\u20131466","DOI":"10.1210\/en.2015-1466"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. J Nature. 1992;355(6357):262-265. doi: https:\/\/doi.org\/10.1038\/355262a0","DOI":"10.1038\/355262a0"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lenzini L, Prisco S, Caroccia B, Rossi GP. Saga of Familial Hyperaldosteronism. Hypertension. 2018;71(6):1010-1014. doi: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11150","DOI":"10.1161\/HYPERTENSIONAHA.118.11150"},{"key":"ref16","unstructured":"Li Y, Li XH, Yuan H. Angiotensin II type-2 receptor-specific effects on the cardiovascular system. Cardiovasc Diagn Ther. 2012;2:56-62. doi: https:\/\/doi.org\/10.3978\/j.issn.2223-3652.2012.02.02"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kem DC, Li H, Velarde-Miranda C, et al. Autoimmune Mechanisms Activating the Angiotensin AT1 Receptor in \u201cPrimary\u201d Aldosteronism. J Clin Endocrinol Metab. 2014;99(5):1790-1797. doi: https:\/\/doi.org\/10.1210\/jc.2013-3282","DOI":"10.1210\/jc.2013-3282"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Seccia TM, Caroccia B, Gomez-Sanchez EP, et al. The Biology of Normal Zona Glomerulosa and Aldosterone-Producing Adenoma: Pathological Implications. Endocr Rev. 2018;39(6):1029-1056. doi: https:\/\/doi.org\/10.1210\/er.2018-00060","DOI":"10.1210\/er.2018-00060"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Williams TA, Mulatero P, Bidlingmaier M, et al. Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. Hypertension. 2015;66(2):248-253. doi: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.05643","DOI":"10.1161\/HYPERTENSIONAHA.115.05643"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Siddiqui AH, Irani RA, Blackwell SC, et al. Angiotensin receptor agonistic autoantibody is highly prevalent in pre- eclampsia: correlation with disease severity. Hypertension. 2010;55:386-393. doi: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.140061","DOI":"10.1161\/HYPERTENSIONAHA.109.140061"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Thway TM, Shlykov SG, Day MC, et al. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation. 2004;110:1612-1619. doi: https:\/\/doi.org\/10.1161\/01.CIR.0000142855.68398.3A","DOI":"10.1161\/01.CIR.0000142855.68398.3A"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Mottl AK, Shoham DA, North KE. Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: a HuGE review. Genet Med. 2008;10(8):560-574. doi: https:\/\/doi.org\/10.1097\/gim.0b013e3181809613","DOI":"10.1097\/GIM.0b013e3181809613"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Monticone S, Else T, Mulatero P, Williams TA. Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. Mol Cell Endocrinol. 2015;399:311-320. doi: https:\/\/doi.org\/10.1016\/j.mce.2014.09.015","DOI":"10.1016\/j.mce.2014.09.015"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Piazza M, Seccia TM, Caroccia B, et al. AT1AA (Angiotensin II Type-1 Receptor Autoantibodies). Hypertension. 2019;74(4):793-799. doi: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13388","DOI":"10.1161\/HYPERTENSIONAHA.119.13388"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Dragun D, M\u00fcller DN, Br\u00e4sen JH, et al . Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352(6):558-569. doi: https:\/\/doi.org\/10.1056\/NEJMoa035717","DOI":"10.1056\/NEJMoa035717"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945-952. doi: https:\/\/doi.org\/10.1172\/JCI4106","DOI":"10.1172\/JCI4106"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Walther T, Wallukat G, Jank A, et al. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 2005;46:1275-1279. doi: https:\/\/doi.org\/10.1161\/01.HYP.0000190040.66563.04","DOI":"10.1161\/01.HYP.0000190040.66563.04"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Yang X, Wang F, Chang H, et al. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J Hypertens. 2008;26:1629-1635. doi: https:\/\/doi.org\/10.1097\/HJH.0b013e328304dbff","DOI":"10.1097\/HJH.0b013e328304dbff"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Herse F, Verlohren S, Wenzel K, et al. Prevalence of agonistic autoan- tibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension. 2009;53:393-398. doi: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.124115","DOI":"10.1161\/HYPERTENSIONAHA.108.124115"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Zhang S, Zheng R, Yang L, et al. Angiotensin type 1 receptor autoantibody from pre- eclamptic patients induces human fetoplacental vasoconstriction. J Cell Physiol. 2013;228:142-148. doi: https:\/\/doi.org\/10.1002\/jcp.24113","DOI":"10.1002\/jcp.24113"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Hubel CA, Wallukat G, Wolf M, et al. Agonistic angioten- sin II type 1 receptor autoantibodies in postpartum women with a his- tory of preeclampsia. Hypertension. 2007;49:612-617. doi: https:\/\/doi.org\/10.1161\/01.HYP.0000256565.20983.d4","DOI":"10.1161\/01.HYP.0000256565.20983.d4"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Siddiqui AH, Irani RA, Blackwell SC, et al. Angiotensin receptor agonistic autoantibody is highly prevalent in pre- eclampsia: correlation with disease severity. Hypertension. 2010;55:386-393. doi: https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.140061","DOI":"10.1161\/HYPERTENSIONAHA.109.140061"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Dragun D. Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol Dial Transplant. 2007;22:1819-1822. doi: https:\/\/doi.org\/10.1093\/ndt\/gfm072","DOI":"10.1093\/ndt\/gfm072"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Taniguchi M, Rebellato LM, Cai J, et al. Higher risk of kidney graft failure in the presence of anti- angiotensin II type-1 receptor antibodies. Am J Transplant. 2013;13:2577-2589. doi: https:\/\/doi.org\/10.1111\/ajt.12395","DOI":"10.1111\/ajt.12395"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Sitkin II, Romanova NY, Platonova NM, et al. Adrenal vein sampling in differential diagnosis of primary aldosteronism on the example of a clinical case. Consilium Medicum. 2019;21(4):109-113. (In Russ.). doi: https:\/\/doi.org\/10.26442\/20751753.2019.4.190334","DOI":"10.26442\/20751753.2019.4.190334"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Yoneda T, Karashima S, Kometani M, et al. Impact of New Quick Gold Nanoparticle-Based Cortisol Assay During Adrenal Vein Sampling for Primary Aldosteronism. J Clin Endocrinol Metab. 2016;101(6):2554-2561. doi: https:\/\/doi.org\/10.1210\/jc.2016-1011","DOI":"10.1210\/jc.2016-1011"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Rossitto G, Battistel M, Barbiero G, et al. The subtyping of primary aldosteronism by adrenal vein sampling. J Hypertens. 2018;36(2):335-343. doi: https:\/\/doi.org\/10.1097\/HJH.0000000000001564","DOI":"10.1097\/HJH.0000000000001564"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"O\u2019Shea PM, O\u2019Donoghue D, Bashari W, et al. C-Metomidate PET\/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice. Clin Endocrinol (Oxf). 2019;90(5):670-679. doi: https:\/\/doi.org\/10.1111\/cen.13942","DOI":"10.1111\/cen.13942"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-148. doi: https:\/\/doi.org\/10.1111\/joim.12831","DOI":"10.1111\/joim.12831"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Powlson AS, Gurnell M, Brown MJ. Nuclear imaging in the diagnosis of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes. 2015;22(3):150-156. doi: https:\/\/doi.org\/10.1097\/MED.0000000000000148","DOI":"10.1097\/MED.0000000000000148"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the Left Ventricle in Primary Aldosteronism Due to Conn\u2019s Adenoma. Circulation. 1997;95(6):1471-1478. doi: https:\/\/doi.org\/10.1161\/01.CIR.95.6.1471","DOI":"10.1161\/01.CIR.95.6.1471"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Lattanzio MR, Weir MR. Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm. Kidney360. 2020;1(10):1146-1154. doi: https:\/\/doi.org\/10.34067\/KID.0000922020","DOI":"10.34067\/KID.0000922020"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/12783\/10243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T14:12:53Z","timestamp":1651327973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/12783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,30]]}},"URL":"https:\/\/doi.org\/10.14341\/probl12783","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"type":"electronic","value":"2308-1430"},{"type":"print","value":"0375-9660"}],"subject":[],"published":{"date-parts":[[2022,2,18]]}}}